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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.12.003Endometrial stromal sarcoma (ESS) is an extremely rare neoplasm accounting for only 0.2% of all uterine
malignancies and for 15–26% of primary uterine sarcomas. The annual incidence of ESS is 1–2 per million
women. Herein, to the best of our knowledge, we present the first reported case of ESS of the vulva in a
50-year-old female presenting with per vaginal spotting over a period of three months. Her past surgical
history included a subtotal hysterectomy and left salpingo-oophorectomy for uterine fibroids ten years
previously. On examination, a 3.5 · 3 · 2 cm cystic mass was found in the right labia majora. The mass
was excised and the diagnosis of endometrial stromal sarcoma was made. Subsequent metastatic workup
was negative and the patient was started on megestrol acetate. She has remained disease free with no
signs or symptoms of recurrent or advanced disease for 28 months.
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mely rare neoplasm accounting for only 0.2%
of all uterine malignancies and for 15–26% of
primary uterine sarcomas.1 The annual incidence of
ESS is 1–2 per million women. Compared to other
uterine malignancies, ESS affects younger women
with a mean age of 42–58 years.2 ESS resembles stro-
mal cells in the proliferative stage of the normal endo-
metrium and are often low-grade, indolent, but
metastatic exhibiting myometrial and/or vascular
invasion.3 The incidence of ESS in extrauterine loca-
tions is exceedingly rare especially in the absence of
metastasis or extension of a primary neoplasm. Prin-
cipal extrauterine sites of ESS include the ovary,
bowel wall, abdomen, peritoneum, pelvis, and
vagina.4–6
Herein, to the best of our knowledge, we present
the ﬁrst reported case of ESS of the vulva in a 50-
year-old female presenting with per vaginal spottingof three months’ duration. A literature review of
ESS is also presented.CASE REPORT
A 50-year-old female, para 8+0 was referred to our
service with per vaginal spotting. Her past medical
history was unremarkable; her previous surgical
history included a subtotal hysterectomy and left sal-
pingo-oophorectomy for uterine ﬁbroids ten years
previously. On clinical examination, a soft yellowish
lesion with hemorrhagic foci, measuring
3.5 · 3 · 2 cm, was found and a Bartholin gland cyst
was suspected. On February 2012, an excisional
biopsy was performed and the rendered histopatholo-
gical diagnosis was low-grade endometrial stromal
sarcoma. Microscopy showed a diffuse cellular inﬁl-
trate composed of monotonous bland looking oval
to spindle cells (simulating endometrial stromal cells)
surrounding arterioles resembling endometrial spiral125
Figure 1. Endometrial stromal sarcoma. (a) A cellular neoplasm composed of bland oval cells surrounding arterioles resembling endometrial spiral
arterioles (hematoxylin and eosin stain, ·200 magnification). (b) A higher magnification microphotograph showing the spindle cells surrounding a
blood vessel (hematoxylin and eosin stain, ·400 magnification).
Figure 2. Endometrial stromal sarcoma. (a) Plaques of hyalinized fibrosis (hematoxylin and eosin stain, ·200 magnification). (b) Areas of tumor
necrosis on the left of the image in contrast to the viable tumor on the right (hematoxylin and eosin stain, ·100 magnification).
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tumor necrosis and hemorrhage were seen, as well
as plaques of hyaline ﬁbrosis (Figure 2). The lesion
was inﬁltrative with poorly deﬁned margins. The sur-
gical resection margins were negative for tumor and
there was no evidence of associated endometriosis.
Moreover, immunohistochemical staining was
strongly positive for CD10, vimentin, estrogen recep-
tor and progesterone receptor (ER and PR) (Figures
3 and 4). Cytokeratin cocktail (CKAE1/AE3) was
moderately positive, whereas h-caldesmon, desmin,
CD34, SMA and S-100 were all negative (Figure
5). The patient was started on megestrol acetate. In
May 2012, surveillance computed tomography of thechest, abdomen, and pelvis displayed an unremarkable
cervix and no signs of metastasis or recurrence. In Jan-
uary 2013, the patient had a positron emission
tomography (PET) scan which was unremarkable;
the patient was therefore kept on megestrol. In July
2013, magnetic resonance imaging (MRI) revealed
an ill-deﬁned lesion in the right side of her perineum
and lower vagina, encasing the urethra, with no lymph
node involvement (Figure 6). The patient was referred
to urology, and a cystoscopy was performed with
unremarkable results. An excisional biopsy was
performed showing a benign polypoid piece of
endocervical mucosa with chronic inﬂammation.
Subsequent cervical smears throughout the patient’sHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
Figure 3. CD10 immunostain showing a strong and diffuse membranous staining of the tumor cells (CD10, Dako, ·400 magnification).
Figure 4. Estrogen receptor immunostain showing a diffuse nuclear reactivity in the tumor cells (ER, Dako, ·400 magnification).
Figure 5. H-caldesmon immunostain showing negative tumor cells in contrast to the internal control smooth muscle cells in the walls of the blood
vessels. (H-caldesmon, Dako, ·200 magnification).
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Figure 6. T1-weighted axial magnetic resonance imaging (MRI) scan showing slight high signal intensity around an ill-defined lesion encasing the
urethra from the right side.
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case report VULVAR EXTRAUTERINE ESSfollow-up were all negative. The patient was main-
tained on megestrol 80 mg once daily and has
remained disease free with no signs or symptoms of
recurrent or advanced disease for the subsequent
28 months of follow-up.DISCUSSION
ESS is an extremely rare neoplasm accounting for only
0.2% of all uterine malignancies and for 15–26% of
primary uterine sarcomas.1 The annual incidence of
ESS is 1–2 per million women. Compared to other
uterine malignancies, ESS affects younger women with
a mean age of 42–58 years.2 The pathogenesis of ESS
is still vague, but hormonal exposure through tamoxi-
fen, estrogens, and conditions such as polycystic
disease of the ovary have been implicated.7 Clinically,
symptoms of ESS are non-speciﬁc and usually include
irregular vaginal bleeding pelvic pain/pressure and an
abdominal mass or discomfort. Diagnosis should
therefore be based on pathological examination.
ESS often forms distinctive ﬁnger-like projections
that invade the myometrium, veins, and lymphatics.
Histologically, ESS is characterized by densely
uniform stromal cells with minimal cellular pleomor-
phism, mild nuclear atypia, and variable mitoses. The
differential diagnosis of our lesion included: smooth
muscle tumors (leiomyosarcoma, cellular leiomyoma),
adenosarcoma, hemangiopericytoma/solitary ﬁbrous
tumor (HPC/SFT), and cellular angioﬁbroma.
Smooth muscle tumors tend to have larger cells
with typical cigar-shaped nuclei. Large thick-walledblood vessels are commonly present, and the small
arterioles that are characteristic of ESS are usually
absent. Immunostains are also helpful in making the
distinction, as smooth muscle tumors are strongly
positive for SMA, desmin and h-caldesmon, and
extensive staining for CD10 is unusual. HPC/SFT
form well-circumscribed masses with neoplastic cells
intimately arranged around a myriad of thin-walled
vessels and partially collapsed branching capillaries.
The absence of large vessels, which often exhibit a
staghorn-like appearance, and the immunostains did
not support this diagnosis. HPC/SFT are strongly
positive for CD34 and SMA. In comparison with
HPC/SFT, ESS shows strong expression of CD10
and PR. ESS is also ER positive and CD34 negative.
We also excluded adenosarcoma with stromal
overgrowth because of the lack of any epithelial ele-
ments, and, subsequently, any periglandular stromal
condensations. Furthermore, the possibility of cellular
angioﬁbroma was considered. However, cellular
angioﬁbromas tend to be well-circumscribed with
uniformly distributed small blood vessels, thick colla-
gen bundles and variable amounts of fat. Cellular
angioﬁbromas can show variable mitotic activity,
though atypical forms, including tumor necrosis, are
absent. There are notable differences in the reported
immunoproﬁle of this tumor. SMA and desmin
expression are positive in <20% and <10% respec-
tively; however, strong diffuse reactivity for CD34 is
reported in about half of such cases.8
The origin of the ESS in our case is unclear.
Despite an unknown route of metastasis and negativeHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
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metastatic workup, a primary metastasizing ESS
should be considered because remote recurrences
occurring after decades from the primary diagnosis
have been previously documented in the literature.9
In a series of 78 patients, Gloor et al. reported higher
local and metastatic recurrence rates in cases where
one or both ovaries were preserved;10 such is the case
in our patient. ESS has also been shown to arise from
ovarian and extraovarian endometriosis.11 Yet our
patient did not have any pathological or radiological
evidence of endometriosis.
According to the hypothesis postulated by
Lauchlan et al., mesenchymal cells present in tis-
sues derived from the coelomic epithelium have
the potential to differentiate into Müllerian-type
epithelium and stroma. This could explain the
occurrence of ESS in extrauterine sites lined by
a coelomic-type of epithelium such as the ovaries,
fallopian tube, and pelvic peritoneum, but not the
vulva or vagina.12,13 However, four cases of
primary ESS occurring in the vagina without evi-
dence of endometriosis or metastasis have been
reported in the literature.14
Treatment of ESS has been challenging due to the
rarity of the disease. Performing prospective random-
ized clinical trials to adjust treatment is difﬁcult;
management has therefore been mainly guided by
retrospective case series and case reports. Treatment
involves various approaches including radiation,Hematol Oncol Stem Cell Ther 8(3) Third` Quarter 2015surgical excision, chemotherapy, or a combination of
surgery and chemotherapy. Hormonal therapy
remains the most studied in the management of
ESS. We therefore report the successful control of
this neoplasm on megestrol acetate after local excision
with negative margins.
ESS has a highly recurrent nature with around
50% of patients presenting with recurrence mostly
after long latency periods.15 They most commonly
recur in the abdomen/pelvis (40–50%) followed by
the lung (25%). However, spine and hematologic
recurrences have also been described in the litera-
ture.16–19
ESS has shown overall survival rates of 65% at ﬁve
years but of 32% in those with extrauterine disease.20
In conclusion, although extremely rare, the diagnosis
of ESS presenting as a Bartholin gland cyst should
be kept in mind especially in patients between the ages
of 40–50 presenting with symptoms of menorrhagia,
dysmenorrhea, and pelvic pain or pressure.DISCLOSURE OF CONFLICT OF INTEREST
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